- $257.51m
- $151.24m
- $53.74m
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Brief: Homology Medicines Reports Third Quarter 2022 Financial Results And Recent Highlights
Brief: Homology Medicines Presents On Design Of Trial Evaluating Its Experimental Therapy HMI-103 For PKU At American Society Of Human Genetics Meeting
Brief: Homology Medicines Appoints Albert Seymour as Chief Executive Officer
U.S. RESEARCH ROUNDUP-Crowdstrike, LPL Financial, Signify Health
U.S. RESEARCH ROUNDUP- Aptinyx, Rapid Micro Biosystems, Trinet Group
Homology Medicines Inc reports results for the quarter ended in June - Earnings Summary
Brief: Homology Medicines Reports Q2 2022 Results
Brief: Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate For Treatment Of Metachromatic Leukodystrophy
Homology Medicines Inc expected to post a loss of 56 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, B&G Foods, Homology Medicines
Brief: Homology Medicines Announces FDA Lifted Clinical Hold On Phenix Gene Therapy Trial For Pku
Several biotechs trading below cash position - Evercore ISI
Brief: Homology Medicines Presents Details Of Optimized HMI-103 Nuclease-Free Gene Editing Candidate
Homology Medicines Inc reports results for the quarter ended in March - Earnings Summary
Brief: Homology Medicines Reports Q1 2022 Financial Results And Recent Highlights
Homology Medicines Inc expected to post a loss of 35 cents a share - Earnings Preview
Homology Medicines Inc reports results for the quarter ended in December - Earnings Summary
Brief: Homology Medicines Reports Fourth Quarter And Full Year 2021 Results